Kane Biotech is addressing chronic wound care challenges by leveraging its revyve portfolio, which includes three FDA-cleared products designed to disrupt biofilms, eliminate bacteria, and enhance the healing environment. With a significant presence in both the U.S. and Canadian markets, the company has expanded its distribution and sales network to meet the healthcare needs of millions suffering from chronic wounds. Kane’s innovative approach targets the persistent issue of biofilms, which contribute to treatment failures, by combining biofilm disruption and antimicrobial action in a single treatment solution. The company aims to convert this potential into commercial growth through new partnerships and an expanded sales team, amidst a growing market opportunity estimated between USD 423 million and USD 493 million.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://kalkinemedia.com/ca/news/featured-news/kane-biotech-tsxvkne-expands-revyve-reach-across-north-american-wound-care-markets
